Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Overview
Date Founded

2014

Headquarters

60 Jubilee Avenue,Milton Park,Abingdon, Oxfordshire OX14 4RX

Type of Company

Public

Employees (Worldwide)

430

Industries

Biotechnology

Company Description

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Adaptimmune Therapeutics PLC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Director

Interim Chief Financial Officer

Chief Operating Officer

Chief Business Officer

Chief Patient Supply Officer

Senior Vice President & Chief Medical Officer

Vice President & Head, BioMarker Research & Development

Head, Autoimmune Group

Head of Process Development

Senior Director, Investor Relations

Board of Directors

Venture Partner & Senior Advisor at New Enterprise Associates

Former Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc.

Treasurer at Boy Scouts of America - National Capital Area Council

Former Partner at MediGene AG

Chief Executive Officer & Director at Adaptimmune Therapeutics PLC

Chief Medical Officer at Moderna, Inc.

General Partner, Washington DC at New Enterprise Associates

Chief Executive Officer at Imvax, Inc.

Paths to Adaptimmune Therapeutics PLC
Potential Connections via
Relationship Science
You
Adaptimmune Therapeutics PLC
Owners & Shareholders
Details Hidden

Matrix Capital Management (MCM) seeks to generate an attractive risk-adjusted return by investing in a concentrated portfolio of long and short positions, following the classic hedge fund model through investments primarily in publicly traded equity securities, and in the case of the Restricted Fund, through both private and public investments. The firm invests primarily in equity securities, typically in the form of common stocks but investments may also include preferred stocks, convertible securities, warrants, stock purchase rights, depositary receipts, shares of investment companies and other equity-related interests. In addition, as market conditions or investment opportunities warrant, investments may include opportunistic investments in debt securities, without restriction as to any minimum rating criteria. MCM''s funds may purchase and write (sell) options on stocks, bonds, currencies or market indices, thus allowing the funds to leverage their returns from specific securities and engage in a wide range of transactions designed to enhance returns, such as securities lending and repurchase agreements. The firm may employ active portfolio management strategies both as a hedge against volatility and to produce additional income and capital appreciation. MCM employs a moderate degree of leverage.

Details Hidden

Matrix Capital Management (MCM) seeks to generate an attractive risk-adjusted return by investing in a concentrated portfolio of long and short positions, following the classic hedge fund model through investments primarily in publicly traded equity securities, and in the case of the Restricted Fund, through both private and public investments. The firm invests primarily in equity securities, typically in the form of common stocks but investments may also include preferred stocks, convertible securities, warrants, stock purchase rights, depositary receipts, shares of investment companies and other equity-related interests. In addition, as market conditions or investment opportunities warrant, investments may include opportunistic investments in debt securities, without restriction as to any minimum rating criteria. MCM''s funds may purchase and write (sell) options on stocks, bonds, currencies or market indices, thus allowing the funds to leverage their returns from specific securities and engage in a wide range of transactions designed to enhance returns, such as securities lending and repurchase agreements. The firm may employ active portfolio management strategies both as a hedge against volatility and to produce additional income and capital appreciation. MCM employs a moderate degree of leverage.

Recent Transactions
Details Hidden

Adaptimmune Therapeutics PLC issued . USD American Depositary Shares

Details Hidden

Adaptimmune Therapeutics PLC issued American Depositary Shares

Transaction Advisors
Underwriter

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Underwriter

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Auditor

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Underwriter

Advised onAdaptimmune Therapeutics PLC issued . USD American Depositary Shares

Clients

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Key Stats and Financials As of 2018
Market Capitalization
$420M
Total Enterprise Value
$355M
Earnings Per Share
$-0.98
Revenue
$59.4M
Net Profit
$-95.4M
EBITDA
$-91.5M
EBITDAMargin
-154%
Total Debt
$0
Total Equity
$247M
Enterprise Value Sales
5.97x
TEVNet Income
-3.72x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
52.42%
Investors
Details Hidden

Oxford Spin-out Equity Management seeks investment opportunities in spin out companies of Isis Innovation Ltd. The fund target companies operating in the fields of diagnostics, med tech, pharma tools and services, other technologies, health technology, biosciences, medical, and drugs. It provides financing for early stage capital requirements.

Details Hidden

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Suppliers
Thermo Fisher Scientific, Inc. Computer Software | Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

BioLife Solutions Inc. Industrial Machinery & Manufacturing | Bothell, Washington

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.

Liberty Property Trust Real Estate Investment Trusts | MALVERN, PA

Liberty Property Trust (NYSE:LRY) is a $6.9 billion real estate investment trust which owns 77.8 million square feet of office and industrial space in more than 21 markets throughout the United States and the United Kingdom (as of Sep. 30, 2012). Founded in 1972 and headquartered outside of Philadelphia, Liberty develops, acquires, leases and manages properties with the mission to enhance people's lives through extraordinary work environments. As an extension of this promise, Liberty is one of the nation's leading developers of high-performance green buildings. Liberty's more than 700 office and industrial properties offer exceptional locations, flexible design, thoughtful amenities, cost efficient operations and state-of-the-art technology to the company's 2,300 tenants. Liberty continuously increases the value of its portfolio through expert management, marketing and development

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adaptimmune Therapeutics PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adaptimmune Therapeutics PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Adaptimmune Therapeutics PLC.